Treatment with a nucleoside polymerase inhibitor reduces shedding of murine norovirus in stool to undetectable levels without emergence of drug-resistant variants

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 3, 2016, Pages 1907-1911

  Rocha Pereira, Joana ^a   Van Dycke, Jana ^a   Neyts, Johan ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

2' METHYLCYTIDINE; FAVIPIRAVIR; VIRUS RNA; 2'-C-METHYLCYTIDINE; AMIDE; CYTIDINE; INTERFERON RECEPTOR; PYRAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FECES ANALYSIS; IN VITRO STUDY; MOUSE; NONHUMAN; NOROVIRUS; NOROVIRUS INFECTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS REPLICATION; VIRUS SHEDDING; VIRUS STRAIN; ANALOGS AND DERIVATIVES; ANIMAL; CALICIVIRIDAE INFECTIONS; DISEASE MODEL; DRUG EFFECTS; FECES; GASTROENTERITIS; GENETICS; GRAFT RECIPIENT; GROWTH, DEVELOPMENT AND AGING; KNOCKOUT MOUSE; VIROLOGY;

AMIDES; ANIMALS; CALICIVIRIDAE INFECTIONS; CYTIDINE; DISEASE MODELS, ANIMAL; FECES; GASTROENTERITIS; MICE; MICE, KNOCKOUT; NOROVIRUS; PYRAZINES; RECEPTORS, INTERFERON; TRANSPLANT RECIPIENTS; VIRUS SHEDDING;

EID: 84960172384     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02198-15     Document Type: Article

References (30)

1. Bok K, Green KY. 2012. Norovirus gastroenteritis in immunocompromised patients. N Engl J Med 367:2126-2132. http://dx.doi.org/10.1056/NEJMra1207742.
2. Roos-Weil D, Ambert-Balay K, Lanternier F, Mamzer-Bruneel MF, Nochy D, Pothier P, Avettand-Fenoel V, Anglicheau D, Snanoudj R, Bererhi L, Thervet E, Lecuit M, Legendre C, Lortholary O, Zuber J. 2011. Impact of norovirus/sapovirus-related diarrhea in renal transplant recipients hospitalized for diarrhea. Transplantation 92:61-69. http://dx.doi.org/10.1097/TP.0b013e31821c9392.
3. Schwartz S, Vergoulidou M, Schreier E, Loddenkemper C, Reinwald M, Schmidt-Hieber M, Flegel WA, Thiel E, Schneider T. 2011. Norovirus gastroenteritis causes severe and lethal complications after chemotherapy and hematopoietic stem cell transplantation. Blood 117:5850-5856. http://dx.doi.org/10.1182/blood-2010-12-325886.
4. Schorn R, Hohne M, Meerbach A, Bossart W, Wuthrich RP, Schreier E, Muller NJ, Fehr T. 2010. Chronic norovirus infection after kidney transplantation: molecular evidence for immune-driven viral evolution. Clin Infect Dis 51:307-314. http://dx.doi.org/10.1086/653939.
5. Capizzi T, Makari-Judson G, Steingart R, Mertens WC. 2011. Chronic diarrhea associated with persistent norovirus excretion in patients with chronic lymphocytic leukemia: report of two cases. BMC Infect Dis 11:131. http://dx.doi.org/10.1186/1471-2334-11-131.
6. Ludwig A, Adams O, Laws HJ, Schroten H, Tenenbaum T. 2008. Quantitative detection of norovirus excretion in pediatric patients with cancer and prolonged gastroenteritis and shedding of norovirus. J Med Virol 80:1461-1467. http://dx.doi.org/10.1002/jmv. 21217.
7. Gallimore CI, Lewis D, Taylor C, Cant A, Gennery A, Gray JJ. 2004. Chronic excretion of a norovirus in a child with cartilage hair hypoplasia (CHH). J Clin Virol 30:196-204. http://dx.doi.org/10.1016/jjcv. 2003.10.007.
8. Rodriguez-Guillen L, Vizzi E, Alcala AC, Pujol FH, Liprandi F, Ludert JE. 2005. Calicivirus infection in human immunodeficiency virus seropositive childrenand adults. J Clin Virol 33:104-109. http://dx.doi.org/10.1016/j.jcv. 2004.09.031.
9. Wingfield T, Gallimore CI, Xerry J, Gray JJ, Klapper P, Guiver M, Blanchard TJ. 2010. Chronic norovirus infection in an HIV-positive patient with persistent diarrhoea: a novel cause. J Clin Virol 49:219-222. http://dx.doi.org/10.1016/jjcv. 2010.07.025.
10. Woodward JM, Gkrania-Klotsas E, Cordero-Ng AY, Aravinthan A, Bandoh BN, Liu H, Davies S, Zhang H, Stevenson P, Curran MD, Kumararatne D. 2015. The role of chronic norovirus infection in the enteropathy associated with common variable immunodeficiency. Am J Gastroenterol 110:320-327. http://dx.doi.org/10.1038/ajg.2014.432.
11. Murata T, Katsushima N, Mizuta K, Muraki Y, Hongo S, Matsuzaki Y. 2007. Prolonged norovirus shedding in infants <6 months of age with gastroenteritis. Pediatr Infect Dis J 26:46-49. http://dx.doi.org/10.1097/01.inf.0000247102.04997.e0.
12. Lai CC, Wang YH, Wu CY, Hung CH, Jiang DD, Wu FT. 2013. A norovirus outbreak in a nursing home: norovirus shedding time associated with age. J Clin Virol 56:96-101. http://dx.doi.org/10.1016/jjcv. 2012.10.011.
13. Aoki Y, Suto A, Mizuta K, Ahiko T, Osaka K, Matsuzaki Y. 2010. Duration of norovirus excretion and the longitudinal course of viral load in norovirus-infected elderly patients. J Hosp Infect 75:42-46. http://dx.doi.org/10.1016/jjhin. 2009.12.016.
14. Rossignol JF, El-Gohary YM. 2006. Nitazoxanide in the treatment of viral gastroenteritis: a randomized double-blind placebo-controlled clinical trial. Aliment Pharmacol Ther 24:1423-1430. http://dx.doi.org/10.1111/j.1365-2036.2006.03128.x.
15. Siddiq DM, Koo HL, Adachi JA, Viola GM. 2011. Norovirus gastroenteritis successfully treated with nitazoxanide. J Infect 63:394-397. http://dx.doi.org/10.1016/jjinf.2011.08.002.
16. Karst SM, Wobus CE, Lay M, Davidson J, Virgin HW, IV. 2003. STAT1-dependent innate immunity to a Norwalk-like virus. Science 299:1575-1578. http://dx.doi.org/10.1126/science.1077905.
17. Wobus CE, Karst SM, Thackray LB, Chang KO, Sosnovtsev SV, Belliot G, Krug A, Mackenzie JM, Green KY, Virgin HW. 2004. Replication of Norovirus in cell culture reveals a tropism for dendritic cells and macrophages. PLoS Biol 2:e432. http://dx.doi.org/10.1371/journal.pbio.0020432.
18. Strong DW, Thackray LB, Smith TJ, Virgin HW. 2012. Protruding domain of capsid protein is necessary and sufficient to determine murine norovirus replication and pathogenesis in vivo. J Virol 86:2950-2958. http://dx.doi.org/10.1128/JVI.07038-11.
19. Thackray LB, Wobus CE, Chachu KA, Liu B, Alegre ER, Henderson KS, Kelley ST, Virgin HW, IV. 2007. Murine noroviruses comprising a single genogroup exhibit biological diversity despite limited sequence divergence. J Virol 81:10460-10473. http://dx.doi.org/10.1128/JVI.00783-07.
20. Nice TJ, Strong DW, McCune BT, Pohl CS, Virgin HW. 2013. A single-amino-acid change in murine norovirus NS1/2 is sufficient for colonic tropism and persistence. J Virol 87:327-334. http://dx.doi.org/10.1128/JVI.01864-12.
21. Nice TJ, Baldridge MT, McCune BT, Norman JM, Lazear HM, Artyomov M, Diamond MS, Virgin HW. 2015. Interferon-lambda cures persistent murine norovirus infection in the absence of adaptive immunity. Science 347:269-273. http://dx.doi.org/10.1126/science.1258100.
22. Johnson AJ, Roehrig JT. 1999. New mouse model for dengue virus vaccine testing. J Virol 73:783-786.
23. Rocha-Pereira J, Jochmans D, Dallmeier K, Leyssen P, Cunha R, Costa I, Nascimento MS, Neyts J. 2012. Inhibition of norovirus replication by the nucleoside analogue 2=-C-methylcytidine. Biochem Biophys Res Commun 427:796-800. http://dx.doi.org/10.1016/j.bbrc.2012.10.003.
24. Rocha-Pereira J, Jochmans D, Dallmeier K, Leyssen P, Nascimento MS, Neyts J. 2012. Favipiravir (T-705) inhibits in vitro norovirus replication. Biochem Biophys Res Commun 424:777-780. http://dx.doi.org/10.1016/j.bbrc.2012.07.034.
25. Rocha-Pereira J, Jochmans D, Debing Y, Verbeken E, Nascimento MS, Neyts J. 2013. The viral polymerase inhibitor 2=-C-methylcytidine inhibits Norwalk virus replication and protects against norovirus-induced diarrhea and mortality in a mouse model. J Virol 87:11798-11805. http://dx.doi.org/10.1128/JVI.02064-13.
26. Pierra C, Amador A, Benzaria S, Cretton-Scott E, D'Amours M, Mao J, Mathieu S, Moussa A, Bridges EG, Standring DN, Sommadossi JP, Storer R, Gosselin G. 2006. Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2=-C-methylcytidine. J Med Chem 49:6614-6620. http://dx.doi.org/10.1021/jm0603623.
27. Julander JG, Shafer K, Smee DF, Morrey JD, Furuta Y. 2009. Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrob Agents Chemother 53:202-209. http://dx.doi.org/10.1128/AAC.01074-08.
28. Morrey JD, Taro BS, Siddharthan V, Wang H, Smee DF, Christensen AJ, Furuta Y. 2008. Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents. Antiviral Res 80:377-379. http://dx.doi.org/10.1016/j.antiviral.2008.07.009.
29. Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL, Gowen BB, Julander JG, Morrey JD. 2009. T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res 82:95-102. http://dx.doi.org/10.1016/j.antiviral.2009.02.198.
30. Arias A, Thorne L, Goodfellow I. 2014. Favipiravir elicits antiviral mutagenesis during virus replication in vivo. ELife 3:e03679. http://dx.doi.org/10.7554/eLife.03679.